title: Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
abstract: Behçet's disease (BD) is a chronic inflammatory disease affecting multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal tract. Intestinal BD is characterized by intestinal ulcerations and gastrointestinal symptoms. The medical treatment of intestinal BD includes corticosteroids and immunosupressants. There have been several reports of tumor necrosis factor-α (TNF-α) blockers being successful in treatment of refractory intestinal BD. Here, we report on a patient who was diagnosed with intestinal BD despite treatment with the fully humanized TNF-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen.
authors: Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea.
authors: Sook Hee
authors: SH
authors: Chung
authors: Soo Jung
authors: SJ
authors: Park
authors: Sung Pil
authors: SP
authors: Hong
authors: Jae Hee
authors: JH
authors: Cheon
authors: Tae Il
authors: TI
authors: Kim
authors: Won Ho
authors: WH
authors: Kim
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D003113:Colonoscopy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007410:Intestinal Diseases / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D013256:Steroids; D000068879:Adalimumab; D001379:Azathioprine
keywords: Adalimumab; Intestinal Behçet’s disease; Tumor necrosis factor-α
references: Ann Rheum Dis. 2007 Apr;66(4):565-6
references: 17124248
references: Dis Colon Rectum. 2007 May;50(5):672-6
references: 17216141
references: Inflamm Bowel Dis. 2009 Dec;15(12):1769-71
references: 19177427
references: J Gastroenterol. 2007 Sep;42(9):737-45
references: 17876543
references: Turk J Gastroenterol. 2009 Mar;20(1):57-61
references: 19330737
references: Inflamm Bowel Dis. 2008 Sep;14(9):1259-64
references: 18393375
references: Mod Rheumatol. 2011 Apr;21(2):184-91
references: 21052764
references: Clin Rheumatol. 2007 Aug;26(8):1383-5
references: 17039261
references: Gut. 2001 Nov;49(5):725-8
references: 11600479
references: J Clin Gastroenterol. 2000 Mar;30(2):144-54
references: 10730919
references: Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii51-3
references: 12379622
references: Gastroenterology. 2001 Mar;120(4):995-9
references: 11231954
references: N Engl J Med. 1999 Oct 21;341(17):1284-91
references: 10528040
references: Int Ophthalmol. 2011 Apr;31(2):165-73
references: 21287227
references: Dis Colon Rectum. 2003 Jan;46(1):118-21
references: 12544532
references: Korean J Intern Med. 2007 Mar;22(1):24-7
references: 17427642